Author/Authors :
HUSSEY, Daniel K Harris Orthopaedic Laboratory - Massachusetts General Hospital , MADANAT, Rami Harris Orthopaedic Laboratory - Massachusetts General Hospital , DONAHUE, Gabrielle S Harris Orthopaedic Laboratory - Massachusetts General Hospital , ROLFSON, Ola Harris Orthopaedic Laboratory - Massachusetts General Hospital , MURATOGLU, Orhun K Harris Orthopaedic Laboratory - Massachusetts General Hospital , MALCHAU, Henrik Harris Orthopaedic Laboratory - Massachusetts General Hospital
Abstract :
Background and purpose — Blood metal ion levels can be an indi-
cator for detecting implant failure in metal-on-metal (MoM) hip
arthroplasties. Little is known about the effect of bilateral MoM
implants on metal ion levels and patient-reported outcomes. We
compared unilateral patients and bilateral patients with either an
ASR hip resurfacing (HR) or an ASR XL total hip replacement
(THR) and investigated whether cobalt or chromium was associ-
ated with a broad spectrum of patient outcomes.
Patients and methods — From a registry of 1,328 patients
enrolled in a multicenter prospective follow-up of the ASR Hip
System, which was recalled in 2010, we analyzed data from 659
patients (311 HR, 348 THR) who met our inclusion criteria.
Cobalt and chromium blood metal ion levels were measured and
a 21-item patient-reported outcome measures (PROMs) question-
naire was used mean 6 years after index surgery.
Results — Using a minimal threshold of > 7 ppb, elevated chro-
mium ion levels were found to be associated with worse health-
related quality of life (HRQoL) (p < 0.05) and hip function (p <
0.05) in women. These associations were not observed in men.
Patients with a unilateral ASR HR had lower levels of cobalt ions
than bilateral ASR HR patients (p < 0.001) but similar levels of
chromium ions (p = 0.09). Unilateral ASR XL THR patients had
lower chromium and cobalt ion levels (p < 0.005) than bilateral
ASR XL THR patients.
Interpretation — Chromium ion levels of > 7 ppb were associ-
ated with reduced functional outcomes in female MoM patients.